药石科技: 关于提前赎回药石转债的第十二次提示性公告

Core Viewpoint - Nanjing PharmaBlock Technology Co., Ltd. has decided to exercise the early redemption of its convertible bonds ("PharmaBlock Convertible Bonds") due to the stock price exceeding the specified threshold, aiming to reduce financial costs and expenses [2][7]. Group 1: Convertible Bond Issuance and Redemption - The company issued 11.5 million convertible bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB [2]. - The bonds were listed on the Shenzhen Stock Exchange on May 18, 2022, under the code "123145" [3]. - The conversion period for the bonds started on October 26, 2022, and will end on April 19, 2028 [3]. - The company has triggered the conditional redemption clause as the stock price was above 130% of the conversion price for at least 15 trading days [2][7]. Group 2: Redemption Terms and Implementation - The redemption price for the bonds is set at 100.62 RMB per bond, which includes accrued interest calculated based on a 1.5% annual interest rate [8]. - The redemption will occur on September 18, 2025, with trading of the bonds ceasing on September 15, 2025 [9]. - The company will notify bondholders of the redemption details daily leading up to the redemption date [9]. Group 3: Conversion Price Adjustments - The conversion price has been adjusted multiple times, with the latest adjustment setting it at 33.61 RMB per share as of May 30, 2025 [5][6]. - The conversion price adjustments are based on the company's stock performance and dividend distributions [4][5].